Cracking the Patent Code: Natco’s Winning Formula
Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term potential—but what's in store for the medium term?
Capital Mind
Ars Technica
Ask a Tech Teacher
Alyson Haley
Slugger O'Toole
Cash Flow Diaries